Cargando…

The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer

Background: Immune checkpoint inhibitors (ICIs) are widely used for treating advanced non-small cell lung cancer (NSCLC). However, some studies indicate that patients with genetic mutations do not benefit from immunotherapy. Hence, this study explored the efficacy of anti-programmed death-1 (PD-1) a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Lei, Li, Fuxia, Zhao, Jing, Zhuo, Xiaoli, Lai, Jingjiang, Wang, Jingliang, Jiang, Fengxian, Xu, Wei, Luan, Fang, Lin, Xiaoyan, Yang, Shuping, Fu, Guobin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158514/ https://www.ncbi.nlm.nih.gov/pubmed/37151388 http://dx.doi.org/10.7150/jca.77199

Ejemplares similares

Effects of Shenling Baizhu powder on pyrotinib-induced diarrhea: analysis of gut microbiota, metabonomics, and network pharmacology
por: Lai, Jingjiang, et al.
Publicado: (2022)

Real-World Use of Immunotherapy for Hepatocellular Carcinoma
por: Sara, Amir, et al.
Publicado: (2023)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
por: Chen, You-Yi, et al.
Publicado: (2021)

Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy
por: Mouritzen, Mette T., et al.
Publicado: (2021)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation
por: Zhao, Jing, et al.
Publicado: (2023)

Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer
por: Pelicon, Veronika, et al.
Publicado: (2023)

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations
por: Jun, Soojin, et al.
Publicado: (2023)

Allergic rhinitis: the eligible candidate to mite immunotherapy in the real world
por: Ciprandi, Giorgio, et al.
Publicado: (2017)

Efficacy of Allergen Immunotherapy for Allergic Asthma in Real World Practice
por: Rhyou, Hyo-In, et al.
Publicado: (2019)

Investigating Established EEG Parameter During Real-World Driving
por: Protzak, Janna, et al.
Publicado: (2018)

Composition of the Gut Microbiota Associated with the Response to Immunotherapy in Advanced Cancer Patients: A Chinese Real-World Pilot Study
por: Cheng, Xi, et al.
Publicado: (2022)

Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort
por: Zou, Zihua, et al.
Publicado: (2022)

Real-World Effectiveness of Ivabradine in Chinese Patients with Chronic Heart Failure: Interim Analysis of the POSITIVE Study
por: Jingmin, Zhou, et al.
Publicado: (2021)

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study
por: Yang, Guangjian, et al.
Publicado: (2022)

Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
por: Xie, Zhaoliang, et al.
Publicado: (2023)

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
por: Liang, Sheng-Kai, et al.
Publicado: (2017)

Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases
por: Moyers, Justin T., et al.
Publicado: (2021)

Systemic reactions to subcutaneous allergen immunotherapy: real-world cause and effect modelling
por: Aue, Adam, et al.
Publicado: (2021)

RCC Real-World Data: Prognostic Factors and Risk Stratification in the Immunotherapy Era
por: Sagie, Shira, et al.
Publicado: (2022)

Sublingual immunotherapy: World Allergy Organization position paper 2013 update
por: Canonica, Giorgio Walter, et al.
Publicado: (2014)

Sub-Lingual Immunotherapy: World Allergy Organization Position Paper 2009
por: Canonica, G. Walter, et al.
Publicado: (2009)

A Review of Psychophysiological Measures to Assess Cognitive States in Real-World Driving
por: Lohani, Monika, et al.
Publicado: (2019)

Real‐World Driving Data Indexes Dopaminergic Treatment Effects in Parkinson's Disease
por: Chang, Jun Ha, et al.
Publicado: (2023)

Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer
por: Rich, Patricia, et al.
Publicado: (2021)

Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
por: Rogala, Paweł, et al.
Publicado: (2022)

Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma
por: Chakiryan, Nicholas H., et al.
Publicado: (2021)

Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
por: Danesi, Valentina, et al.
Publicado: (2022)

Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC
por: Ismail, R. K., et al.
Publicado: (2023)

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
por: Blancas, I., et al.
Publicado: (2021)

A Comparative Study of Colour Effects on Cognitive Performance in Real-World and VR Environments
por: Xia, Guobin, et al.
Publicado: (2021)

First-Line Pazopanib Treatment in Metastatic Renal Cell Carcinoma: Real-World Data From a Single Chinese Center
por: Wang, Bin, et al.
Publicado: (2020)

Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC
por: Ismail, R. K., et al.
Publicado: (2023)

Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations
por: Garassino, Marina C., et al.
Publicado: (2023)

Real‐world benefits of allergen immunotherapy for birch pollen‐associated allergic rhinitis and asthma
por: Wahn, Ulrich, et al.
Publicado: (2018)

Real world evidence of long-term benefits from allergen-specific immunotherapy (AIT)
por: Scadding, Guy
Publicado: (2021)

Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions
por: Economopoulou, Panagiota, et al.
Publicado: (2021)

Persistence in allergen immunotherapy: A longitudinal, prescription data‐based real‐world analysis
por: Pfaar, Oliver, et al.
Publicado: (2023)

Real-world safety and effectiveness analysis of low-dose preschool sesame oral immunotherapy
por: Chua, Gilbert T., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g365val71u1hf731bg3ved4t7c